Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany.
Eur Arch Psychiatry Clin Neurosci. 2010 Aug;260(5):407-17. doi: 10.1007/s00406-009-0091-4. Epub 2010 Jan 3.
The search of the genetic predictors of response to antidepressants is a rapidly expanding field. A large number of clinical studies are reporting partly inconsistent results. Emerging new results focus on new candidate single nucleotide polymorphisms--particularly in the 5HT2a-receptor gene and the gene coding for the co-chaperone FKBP5. The impact of the 5HTTLPR polymorphism on therapeutic outcome and side effects under treatment with SSRIs has to be viewed in a more complex manner than previously proposed. All replicable genetic associations display only a very modest effect. Despite of enormous research efforts, currently pharmacogenetics of therapeutic effects and of side effects of antidepressants are unable to guide decisions on the selection of the most beneficial drug for an individual patient.
抗抑郁药反应的遗传预测因子的研究是一个快速发展的领域。大量的临床研究报告了部分不一致的结果。新兴的新结果集中在新的候选单核苷酸多态性上，特别是在 5HT2a 受体基因和编码共伴侣 FKBP5 的基因上。5HTTLPR 多态性对 SSRI 治疗的疗效和副作用的影响比以前提出的要复杂得多。所有可重复的遗传关联仅显示出非常微小的作用。尽管进行了巨大的研究努力，但目前抗抑郁药治疗效果和副作用的药物遗传学还无法指导针对个体患者选择最有效药物的决策。
